Abstract
Background: We performed an updated meta-Analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease. Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects. Results: Seven studies (total n = 2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference = 0.13), activity of daily living scores (standardized mean difference = 0.10), and global assessment scores (standardized mean difference = 0.15). In addition, cognitive function scores (standardized mean difference = 0.13, P = .06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects. Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated..
Original language | English |
---|---|
Pages (from-to) | 1-11 |
Number of pages | 11 |
Journal | International Journal of Neuropsychopharmacology |
Volume | 18 |
Issue number | 5 |
DOIs | |
Publication status | Published - 01-03-2015 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)